Evaluation of Drug-Related Problems in Chronic Kidney Disease Patients

Tasneem M. Shouqair ¹, Syed Arman Rabbani ², Sathvik B. Sridhar ¹, Martin T. Kurian ²

¹. Department of Clinical Pharmacy and Pharmacology, Ras Al Khaimah College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, ARE ². Department of Nephrology, Ibrahim Bin Hamad Obeidullah Hospital, Ras Al Khaimah, ARE

Corresponding author: Syed Arman Rabbani, arman@rakmhsu.ac.ae

Abstract

Background
Chronic kidney disease (CKD) is a challenging global health problem with increasing prevalence worldwide. Concurrency of CKD and comorbidities results in the use of multiple medications and exposing patients to polypharmacy. Polypharmacy in CKD is common across all the stages of the disease and leads to poor medication adherence, higher healthcare costs, and drug-related problems, such as drug-drug interactions (DDIs) and adverse drug reactions (ADRs). DDIs and ADRs in CKD patients may lower the quality of life, increase the length of hospital stay, and augment the risks of morbidity and mortality.

Methodology
This was a hospital-based, prospective, cross-sectional study conducted in a secondary care hospital. The study population comprised 130 adult CKD patients admitted to the nephrology department including those on maintenance hemodialysis. Study-related data were obtained from the electronic patient case records. Medications prescribed to the patients were analyzed for potential DDIs (pDDIs) using Portable Emergency and Primary Care Information Database (PEPID 12.1) drug interaction checker. All observed and reported suspected ADRs related to the prescribed drugs were evaluated for causality, severity, preventability, and predictability.

Results
Out of the 130 patients, majority were males (n = 71, 54.6%), in the age group of 61-70 years (n = 45, 34.6%), and belonged to CKD stage 5 (n = 105, 80.8%). The mean number of drugs prescribed was 11.1 ± 3.8 per patient. The prevalence of pDDIs was found to be 89.2%. Upon analysis by the PEPID database, 708 pDDIs with 215 different pairs of interacting drugs were identified. Polypharmacy (odds ratio (OR): 62.34, 95% confidence interval (CI): 7.97-487.64, p < 0.001) was identified as an independent predictor of the occurrence of pDDIs. Negative binomial regression analysis revealed that dyslipidemia (incidence rate ratio (IRR): 2.7, 95% CI 2.09-3.48, p < 0.001) and diabetes (IRR: 1.2, 95% CI 1.01-1.54, p = 0.040) increased the probability of occurrence of pDDI by 2.7 and 1.2 folds, respectively. Furthermore, the likelihood of pDDI increased with every one-day increase in the length of hospital stay (IRR: 1.02, 95% CI 1.00-1.03, p = 0.015) by 1.02 times and polypharmacy (IRR: 6.30, 95% CI 3.04-13.02, p < 0.001) by 6.3 times. The incidence of ADRs was found to be 10.7%. Majority of suspected ADRs were possible (n = 7, 50.0%), of mild to moderate severity (n = 7, 50.0%), and non-preventable (n = 8, 57.1%) type.

Conclusions
This study investigated two important drug-related problems, pDDIs, and ADRs, in the CKD population. High proportion of CKD patients in the study had pDDIs. Comorbid conditions such as dyslipidemia and diabetes mellitus, length of hospital stay, and polypharmacy were significantly associated with increased likelihood of pDDIs. Furthermore, there was a burden of ADRs in the study population, of which most ADRs were possible and of mild to moderate severity. Prevention, identification, and resolution of these problems in CKD patients is important and can be achieved through medication optimization, which requires a proactive interdisciplinary collaboration between clinicians, clinical pharmacists, and other healthcare professionals.

Introduction
Chronic kidney disease (CKD) is a challenging global health problem with growing prevalence worldwide and is linked to increased morbidity, mortality, and healthcare expenditures [1]. CKD is associated with several complications affecting different organ systems and patients with CKD experience poor quality of life [2].
Concurrence of CKD and comorbidities results in the use of multiple medications making the management of CKD particularly challenging [3]. Polypharmacy, the concomitant use of five or more medications, is a significant and rising public health concern [4]. Polypharmacy in CKD is common across all the stages of the disease and is linked to poor medication adherence, higher healthcare costs, and, most significantly, drug-related problems, such as drug-drug interactions (DDIs) and adverse drug reactions (ADRs) [5,6].

DDIs are changes that occur in the effects of one drug due to the concomitant administration of another drug for the same or different diseases and can be a result of pharmacokinetic or pharmacodynamic alterations [7]. DDIs account for 2–6% of all hospital admissions and have been implicated in adverse clinical outcomes. The estimated prevalence of DDIs in CKD patients ranges from 56.9% and 89.1% [8]. Early identification of potential DDIs (pDDIs) is vital to implement appropriate preventive measures and interventions [8]. Furthermore, ADRs are prevalent, frequently serious, and potentially preventable in CKD patients [9]. Therefore, assessing the causality, severity, and preventability of ADRs is essential to reduce the likelihood of associated complications [10].

DDIs and ADRs in CKD patients may lower the quality of life, increase the length of hospital stay and augment the risks of morbidity and mortality [11]. Therefore, prevention, identification, and resolution of these problems are very important for this vulnerable CKD population, which, in turn, will lead to better clinical outcomes. This can be achieved through medication optimization that requires a proactive interdisciplinary collaboration between clinicians, clinical pharmacists, and other healthcare professionals [12].

Evaluation of drug-related problems such as pDDIs and ADRs among CKD population of United Arab Emirates (UAE) is important for several reasons, increasing the burden of the disease in the local population [13], largely unknown state of CKD care in the region, and paucity of studies addressing drug-related problems in its CKD population. Therefore, the present study was undertaken to assess pDDIs and ADRs among CKD patients presenting to the nephrology department of a secondary hospital in the UAE.

Materials And Methods
Study setting and population
The study was conducted at Ibrahim Bin Hamad Obaidullah Hospital, which is a secondary care hospital in Ras Al Khaimah, UAE. The hospital is a multispecialty center with 167 beds and specialties such as internal medicine, nephrology, cardiology, neurology, emergency medicine, geriatrics, and psychiatry. The study population included adult CKD patients admitted to the nephrology department including patients on maintenance hemodialysis at the study site.

Study design and sample size
This was a hospital-based, prospective, cross-sectional study. A priori statistical sample size calculation was performed using Epi Info™ software version 7.2 by the Centers for Disease Control and Prevention (CDC). Single population proportion formula was used to estimate the sample size using CKD prevalence in the region 4.6% [14], with a 4% margin of error at 95% confidence interval (CI) level and design effect of 1.0, the estimated sample size came out to be 105 patients. A total of 130 CKD patients were included in the study.

Variable definitions
CKD and stages of CKD were defined as per the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the evaluation and management of CKD [15]. Diabetes mellitus was defined as the use of antidiabetic drugs or HbA1c of >6.5%. Anemia was defined as hemoglobin of <13 g/dL in males and <12 g/dL in females. Hypertension was defined as the use of antihypertensive drugs or systolic blood pressure of >140 mmHg and/or diastolic blood pressure of >90 mmHg. Dyslipidemia was defined as the use of lipid-lowering medications or total cholesterol of >5.2 mmol/L and/or triglycerides of >1.7 mmol/L and low-density lipoprotein cholesterol of >2.6 mmol/L. Hyperphosphatemia was defined as the use of phosphate binders or serum phosphate level of >1.45 mmol/L. Vitamin D deficiency was defined as the use of vitamin D preparations or serum 25-hydroxyvitamin D level of <50 nmol/L. Polypharmacy was defined as using five or more drugs concomitantly.

Data collection and analysis
Study data were obtained from the electronic patient case records by the investigators. The collected data included demographic, clinical, and laboratory data. The drugs prescribed to the patients were recorded and analyzed for pDDIs using Portable Emergency and Primary Care Information Database (PEPID 12.1) drug interaction checker [16]. The identified pDDIs were characterized as pharmacokinetic (PK), pharmacodynamic (PD), or other based on the mechanism and graded as non-significant, minor, moderate, significant, or life-threatening based on the level of concern [16]. All observed and reported suspected ADRs related to the prescribed drugs were documented and evaluated for causality [17,18], severity [19], preventability [20], and predictability [20].
Data were reviewed for completeness, sorted, and analyzed using Statistical Package for the Social Sciences (SPSS) version 26.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were used to analyze the study variables and the results were reported as frequency, mean, and standard deviation (SD) with 95% CIs. Univariate and multivariate logistic regression analyses were performed to identify the predictors of pDDIs. The association between the number of pDDIs and CKD patients’ variables was established using a negative binomial regression model and results were reported as incidence rate ratios (IRR) with 95% CI that determined the strength of associations. P-values of <0.05 were considered statistically significant.

**Ethical considerations**

Ethical approval was obtained from the Institutional Ethics Committee of Ras Al Khaimah (RAK) Medical and Health Sciences University (RAKMHSU-REC-016-2019-PG-P) and the Ministry of Health and Prevention Research Ethics Committee/RAK Subcommittee (MOHAP/REC/2019/44-2019-PG-P), UAE.

**Results**

**Demographic and clinical characteristics**

Of the 130 patients enrolled in the study, majority were males (n = 71, 54.6%), belonged to the age group of 61–70 years (n = 45, 34.6%), were non-smokers (n = 127, 97.7%) and non-alcoholic (n = 130, 100%), with no previous allergic history (n = 116, 89.2%), and belonged to CKD stage 5 (n = 105, 80.8%). The majority of the patients had hypertension as the comorbid condition (n = 126, 96.9%). The number of associated comorbidities varied between two to eight with a mean number of 5.5 ± 1.3 comorbidities. Hospital stay varied among patients from a minimum of one day to a maximum of 25 days with an average length of hospital stay of 3.9 ± 5.7 days. In total, 1,494 drugs were administered to 130 CKD patients. The mean number of drugs administered was 11.1 ± 3.8 per patient. The majority of the patients (n = 116, 89.2%,) were prescribed more than five drugs. The demographic and clinical characteristics are represented in Table 1.

| Variables                   | N (%)/ Mean ± SD | 95% CI  |
|-----------------------------|------------------|---------|
| Gender, n (%)               |                  |         |
| Female                      | 59 (45.4)        | 36.9-53.8 |
| Male                        | 71 (54.6)        | 46.2-63.1 |
| Age (years), n (%)          |                  |         |
| 18–30                       | 7 (5.4)          | 1.5-10  |
| 31–40                       | 9 (6.9)          | 3.1-12.3 |
| 41–50                       | 18 (13.8)        | 8.5-20  |
| 51–60                       | 23 (17.7)        | 11.5-24.6 |
| 61–70                       | 45 (34.6)        | 25.4-42.3 |
| 71–80                       | 22 (16.9)        | 10.6-23.8 |
| 81–90                       | 6 (4.6)          | 1.5-8.5  |
| Nationality, n (%)          |                  |         |
| Arab                        | 109 (83.8)       | 76.9-90 |
| Non-Arab                    | 21 (16.2)        | 10.0-23.1 |
| Tobacco use, n (%)          |                  |         |
| Yes                         | 3 (2.3)          | 0.0-5.4  |
| No                          | 127 (97.7)       | 94.6-100 |
| Alcohol use, n (%)          |                  |         |
| No                          | 130 (100)        | 100-100 |
| Previous allergic history, n (%) |        |         |
| Yes                         | 14 (10.8)        | 6.2-16.9 |
| No                          | 116 (89.2)       | 83.1-93.8 |
| CKD stage, n (%)            |                  |         |
| Stage 1                     | 0.0              | 0.0      |
| Stage 2                     | 2 (1.5)          | 0.3-8    |
| Stage 3                     | 10 (7.7)         | 3.1-12.3 |
| Stage 4                     | 11 (8.5)         | 3.8-13.1 |
| Stage 5                     | 107 (82.3)       | 76.2-88.5 |
| Number of comorbidities, n (%) |          |         |
| ≤4                          | 20 (15.4)        | 9.2-22.3 |
Type of comorbidities, n (%)  

| Comorbidity                  | n (%)       | 95% CI          |
|-----------------------------|-------------|-----------------|
| Hypertension                | 126 (96.9)  | 93.1-99.2       |
| Hyperphosphatemia           | 109 (83.8)  | 79.9-89.2       |
| Anemia                      | 108 (83.1)  | 76.2-89.2       |
| Diabetes mellitus           | 92 (70.8)   | 63.1-77.7       |
| Dyslipidemia                | 88 (67.7)   | 58.5-75.4       |
| Vitamin D deficiency        | 75 (57.7)   | 48.5-66.2       |
| Secondary Hyperparathyroidism | 53 (40.8) | 32.3-50         |
| Cardiovascular diseases     | 43 (33.1)   | 25.4-41.5       |
| Neurological diseases       | 19 (14.6)   | 9.2-20.8        |

Polypharmacy, n (%)  

| Polypharmacy | n (%)       | 95% CI          |
|--------------|-------------|-----------------|
| <5 drugs     | 14 (10.8)   | 5.4-16.2        |
| ≥5 drugs     | 116 (89.2)  | 83.8-94.6       |

Length of hospital stay (days), n (%)  

| Length of stay | n (%)       | 95% CI          |
|----------------|-------------|-----------------|
| <7 days        | 104 (80.0)  | 73.1-86.2       |
| ≥7 days        | 26 (20.0)   | 13.8-26.9       |

Systolic blood pressure (mmHg), mean ± SD  

| Blood Pressure | Mean ± SD | 95% CI          |
|---------------|-----------|-----------------|
| Systolic      | 150.1 ± 22.1 | 146.3 ± 19.6-153.9 ± 24.5 |
| Diastolic     | 76.1 ± 14.5  | 73.6 ± 12.6-78.7 ± 16.2  |

Hemoglobin (g/dL)  

| Hemoglobin | Mean ± SD | 95% CI          |
|------------|-----------|-----------------|
| 10.8 ± 1.6 | 10.6 ± 1.3-11.1 ± 1.8 |

Serum creatinine (mmol/L)  

| Creatinine | Mean ± SD | 95% CI          |
|------------|-----------|-----------------|
| 654.0 ± 349.1 | 594.1 ± 268.8-718.1 ± 438.7 |

Urea (mmol/L)  

| Urea | Mean ± SD | 95% CI          |
|------|-----------|-----------------|
| 19.8 ± 9.3  | 18.2 ± 7.8-21.5 ± 10.8 |

Serum phosphorus (mmol/L)  

| Phosphorus | Mean ± SD | 95% CI          |
|------------|-----------|-----------------|
| 1.3 ± 0.6  | 1.2 ± 0.5-1.4 ± 0.7 |

Serum calcium (mmol/L)  

| Calcium | Mean ± SD | 95% CI          |
|---------|-----------|-----------------|
| 2.0 ± 0.2  | 2.0 ± 0.1-2.1 ± 0.2 |

Serum potassium (mmol/L)  

| Potassium | Mean ± SD | 95% CI          |
|-----------|-----------|-----------------|
| 4.5 ± 0.9  | 4.3 ± 0.7-4.6 ± 1.0 |

Serum sodium (mmol/L)  

| Sodium | Mean ± SD | 95% CI          |
|--------|-----------|-----------------|
| 137.5 ± 3.2 | 136.9 ± 2.8-138.0 ± 3.6 |

RBG (mmol/l)  

| RBG | Mean ± SD | 95% CI          |
|-----|-----------|-----------------|
| 8.0 ± 4.1  | 7.4 ± 3.2-8.7 ± 5.1 |

HbA1c (%)  

| HbA1c | Mean ± SD | 95% CI          |
|-------|-----------|-----------------|
| 5.5 ± 1.1  | 5.4 ± 0.8-5.7 ± 1.2 |

### Table 1: Demographic, clinical, and laboratory characteristics of CKD patients.

Cardiovascular disease is defined as myocardial infarction, cardiac arrhythmia, heart failure, peripheral artery disease, or stroke. Neurological disease is defined as epilepsy, Alzheimer’s disease, depression, schizophrenia, or anxiety. Polypharmacy is defined as intake of five or more medications per day.

SD: standard deviation; CI: confidence interval; CKD: chronic kidney disease; RBG: random blood glucose

### Drug-related problems

**Potential Drug-Drug Interactions**

The prevalence of pDDIs in our study was 89.2% (116 patients had pDDIs). Upon analysis using the PEPID database, a total of 708 pDDIs with 215 different pairs of interacting drugs were identified in 116 patients. The mean pDDIs per patient was found to be 5.4 ± 4.4. The majority of the patients had (n = 60, 46.2%) had 1-5 interactions, followed by 6-10 interactions (n = 39, 30.0%). Eight interactions were life-threatening, 55 interactions were significant, and 152 interactions were moderate according to the level of concern. The common pDDIs reported were between aspirin and enoxaparin (n = 30, 23.1%), insulin and linagliptin (n = 22, 16.9%), moxodaridine and bisoprolol (n = 14, 10.8%), clopidogrel and enoxaparin (n = 13, 10.0%), linagliptin and gliclazide (n = 8, 6.2%), and aspirin and urokinase (n = 6, 4.6%). Table 2 represents the common pDDIs detected in the study. Figure 1 represents the distribution of pDDIs in the study.
| pDDIs                   | Percentage | Interaction types       | Pharmacological consequences                                                                 |
|-----------------------|------------|------------------------|---------------------------------------------------------------------------------------------|
| Aspirin-enoxaparin    | 23.0       | Pharmacodynamic        | Aspirin may enhance the anticoagulant effect of enoxaparin. Increased possibility of bleeding |
| Insulin-linagliptin   | 16.9       | Other                  | Linagliptin may enhance the hypoglycemic effect of insulin                                   |
| Moxonidine-bisoprolol | 10.7       | Other                  | Moxonidine may enhance AV-blocking effect of bisoprolol. Significance of this interaction may be more in heart failure patients |
| Clopidogrel-enoxaparin| 10.0       | Pharmacodynamic        | Clopidogrel may enhance the anticoagulant effect of enoxaparin. Increased possibility of bleeding |
| Linagliptin-gliclazide | 6.1        | Other                  | Linagliptin may enhance the hypoglycemic effect of gliclazide                                 |
| Aspirin-urokinase     | 4.6        | Pharmacodynamic        | Aspirin may enhance the anticoagulant effect of urokinase. Increased possibility of bleeding  |
| Sevelamer-levothyroxine| 3.8        | Other                  | Sevelamer may decrease the serum concentration of levothyroxine                              |
| Carvedilol-cinacalcet | 3.0        | Pharmacokinetic        | Cinacalcet may increase the serum concentration of carvedilol. Increased possibility of hypotension and bradycardia |
| Loratadine-ipratropium bromide | 2.3 | Pharmacodynamic | Ipratropium may enhance the anticholinergic effect of loratadine. Increased possibility of tachycardia, constipation, urinary retention, pupil dilation, vasodilation, and hyperthermia |
| Furosemide-potassium chloride | 1.5 | Pharmacodynamic | Potassium chloride increases and furosemide decreases serum potassium. Net effect of interaction is not clear |

**TABLE 2: Common potential drug-drug interactions reported in the study.**

pDDI: potential drug-drug interactions; Other: interaction type other than pharmacokinetic or pharmacodynamic
Factors Associated With Potential Drug-Drug Interactions

In univariate logistic regression analysis, age (odds ratio (OR): 1.04, 95% CI: 1.0-1.07, p = 0.038), Arab nationality (OR: 3.46, 95% CI: 0.48-9.24, p = 0.044), more than four comorbidities (OR: 5.46, 95% CI: 1.65-18.08, p = 0.005), and polypharmacy (OR: 39.96, 95% CI: 9.72-164.25, p < 0.001) were significantly associated with occurrence of pDDIs. However, the results of multivariate logistic regression analysis revealed that Arab nationality (OR: 14.21, 95% CI: 0.38-49.74, p = 0.015) and polypharmacy (OR: 62.34, 95% CI: 7.97-487.64, p < 0.001) were the independent predictors of occurrence of pDDIs in our study population (Table 3).
## TABLE 3: Univariate and multivariate analyses of factors associated with the occurrence of potential drug-drug interactions in CKD patients.

Polypharmacy is defined as the intake of five or more medications per day.

| Variable (reference)         | Univariate model | Multivariate model |
|-----------------------------|------------------|--------------------|
|                             | OR (95% CI)      | P-value            | OR (95% CI)      | P-value            |
| Age, years                  | 1.04 (1.00-1.07) | 0.038              | 1.01 (0.96-1.06) | 0.651              |
| Gender (Male)               |                  |                    |                  |                    |
| Female                      | 1.57 (0.50-4.96) | 0.444              | 0.87 (0.17-4.45) | 0.873              |
| Nationality (Non-Arab)      |                  |                    |                  |                    |
| Arab                        | 3.46 (0.48-9.24) | 0.044              | 14.21 (0.38-49.74) | 0.015              |
| CKD stage (Stages 1–4)      |                  |                    |                  |                    |
| Stage 5                     | 1.30 (0.33-5.12) | 0.699              | 0.69 (0.06-7.61) | 0.766              |
| Length of hospital stay, days | 1.02 (0.96-1.12) | 0.770              | 1.01 (0.88-1.16) | 0.880              |
| Number of comorbidities (≤4) |                  |                    |                  |                    |
| >4                          | 5.46 (1.66-18.08) | 0.005              | 3.01 (0.44-20.19) | 0.257              |
| Polypharmacy (<5 drugs)     |                  |                    |                  |                    |
| ≥5 drugs                    | 39.96 (9.72-164.25) | <0.001 | 62.34 (7.97-487.64) | <0.001 |
| Type of comorbidities (No)  |                  |                    |                  |                    |
| Diabetes                    | 2.74 (0.89-8.45) | 0.079              | 3.30 (0.66-16.40) | 0.144              |
| Anemia                      | 0.80 (0.16-3.85) | 0.781              | 1.16 (0.08-16.53) | 0.913              |
| Hyperphosphatemia           | 1.48 (0.37-5.85) | 0.572              | 0.23 (0.01-3.55) | 0.291              |

Furthermore, negative binomial regression analysis was performed to establish the association between the number of pDDIs and different factors associated with CKD patients. The results revealed that the probability of occurrence of a pDDI increased 2.7 folds (IRR: 2.7, 95% CI: 2.09-3.48, p < 0.001) in the presence of dyslipidemia and 1.2 folds in the presence of diabetes mellitus (IRR: 1.2, 95% CI: 1.01-1.54, p = 0.040) as comorbid conditions. With every one-day increase in the length of hospital stay, the likelihood of pDDIs increased 1.02 times (IRR: 1.01, 95% CI: 1.00-1.03, p = 0.015) and polypharmacy (five or more medications) increased the likelihood of pDDIs by 6.3 times (IRR: 6.30, 95% CI: 3.04-13.02, p < 0.001) compared to no polypharmacy (Table 4).
| Variable (reference)                  | IRR   | 95% CI      | P-value |
|--------------------------------------|-------|-------------|---------|
| Age, years                           | 1.0   | 0.99-1.01   | 0.223   |
| Gender (Male)                        |       |             |         |
| Female                               | 0.94  | 0.80-1.09   | 0.425   |
| Nationality (Non-Arab)               |       |             |         |
| Arab                                 | 1.22  | 0.97-1.52   | 0.080   |
| CKD stage (Stage 2 and 3)            |       |             |         |
| Stage 4                              | 0.73  | 0.50-1.07   | 0.106   |
| Stage 5                              | 0.87  | 0.67-1.14   | 0.332   |
| Length of hospital stay, days        | 1.02  | 1.0-1.03    | 0.015   |
| Number of comorbidities (≤4)         |       |             |         |
| >4                                   | 1.02  | 0.73-1.41   | 0.908   |
| Type of comorbidities (No)           |       |             |         |
| Hypertension                         | 0.76  | 0.41-1.41   | 0.385   |
| Diabetes                             | 1.24  | 1.01-1.54   | 0.040   |
| Anemia                               | 1.01  | 0.82-1.25   | 0.879   |
| Dyslipidemia                         | 2.70  | 2.09-3.48   | <0.001  |
| Hyperphosphatemia                    | 0.98  | 0.77-1.25   | 0.922   |
| Polypharmacy (<5)                    |       |             |         |
| ≥5                                   | 6.30  | 3.04-13.02  | <0.001  |

**TABLE 4: Negative binomial regression model demonstrating the association between the number of potential drug-drug interactions and different variables in CKD patients.**

Polypharmacy is defined as the intake of five or more medications per day.

IRR: incidence rate ratio; CI: confidence interval

---

**Adverse Drug Reactions**

During the study period, a total of 14 ADRs were identified in 14 patients. Hypoglycemia (n = 3, 21.4%) and hyperkalemia (n = 3, 21.4%) were the most common suspected ADRs, followed by hypokalemia, elevated liver enzyme, and hyponatremia (n = 14.3% each). The spectrum of suspected ADRs and associated drugs is represented in Table 5. Furosemide was the most common drug involved in ADRs (n = 4, 28.5%), followed by linagliptin and valsartan (n = 3, 21.4%).
ADRs: adverse drug reactions

| ADRs                | Associated drugs | n (%)  |
|---------------------|------------------|--------|
| Edema               | Amlodipine       | 1 (7.1)|
| Dizziness           | Moxonidine       | 1 (7.1)|
| Hypokalemia         | Furosemide       | 2 (14.3)|
| Elevated liver enzymes | Atorvastatin  | 2 (14.3)|
| Hyponatremia        | Furosemide       | 2 (14.3)|
| Hypoglycemia        | Linagliptin      | 3 (21.4)|
| Hyperkalemia        | Valsartan        | 3 (21.4)|

**TABLE 5: Suspected adverse drug reactions and associated drugs.**

ADRs: adverse drug reactions

Causality Assessment of Suspected Adverse Drug Reactions

According to the Naranjo causality scale, the majority of suspected ADRs were possible (n = 7, 50.0%), followed by probable (n = 5, 35.7%), and definite (n = 2, 14.3%). Based on the World Health Organization probability scale, there were 11 (78.6%) possible and three (21.4%) probable ADRs. Severity assessment using Hartwig’s severity scale categorized seven (50.0%) ADRs as moderate and the remaining seven (50.0%) as mild. Preventability assessment using modified Schumock and Thornton scale indicated that eight (57.1%) ADRs were not preventable and six (42.9%) were probably preventable (Figure 2).
For the management of ADRs, the suspected drug was withdrawn in 57.1% of cases, dose alteration was done in 35.7% of cases, and no change in the prescription was done in 7.1% of cases (Figure 2).

Discussion
The present study sheds light on two common drug-related problems, DDIs and ADRs, among CKD patients. The risk of drug-related problems in CKD patients is high because of increased medication burden and impaired renal function. The estimated prevalence of DDIs in CKD patients ranges from 56.9% to 89.1% [8]. The present study reports a high prevalence of pDDIs (89.2%) in patients with CKD. A similar finding was reported in a study conducted by Al-Ramahi and colleagues in which the prevalence of pDDIs among 275 hemodialysis patients was found to be 89.1% [21]. Another study conducted by Chaudhary and colleagues reported the prevalence of pDDIs to be 78.3% [22]. These findings can be attributed to the fact that majority of the CKD patients in the study (116 out of 130) were prescribed more than five drugs, with a mean number of drugs prescribed per patient being 11.1 ± 3.8. High medication burden in CKD patients has been linked to increased prevalence of pDDIs [11,23].

The majority of the patients (46.2%) had 1-5 interactions, followed by 6-10 interactions (30.0%), with mean pDDIs per patient of 5.4 ± 4.4. Similar pDDI distribution among CKD patients has been reported by previous studies [21,24]. Different studies have employed different drug interaction checkers such as Micromedex, Medscape, LexiComp, and DrugReax, each with its own identification and classification of DDIs. PEPID 12.1 drug interaction checker was used to analyze pDDIs in this study. PEPID grades DDIs based on the level of concern as non-significant, minor, moderate, significant, and life-threatening. Most pDDIs (70.7%) identified were of moderate level of concern. Moderate DDIs may require monitoring of drug therapy and, if required, dose adjustments depending on patient response [16]. Previous investigations on cohorts of CKD patients found that majority of DDIs were of the moderate type, followed by minor or mild and significant type. Major or life-threatening DDIs accounted only for 0.1-1% of all observed DDIs [24].

Univariate logistic regression analysis revealed that age, higher number of comorbidities, and polypharmacy...
were significantly associated with occurrence of pDDIs in the study population. These findings are in agreement with a study conducted by Al-Ramahi and colleagues [21] in which higher age, higher number of comorbid conditions, and more than five medications were significantly associated with the number of potential interactions. Multivariate logistic regression identified polypharmacy as an independent predictor of the occurrence of pDDIs. These findings can be attributed to the multimorbid aged CKD patients in advanced stage of the disease requiring management with complex therapeutic regimens consisting of multiple drugs. Likewise, previous studies have also found polypharmacy to be significantly associated with drug-related problems [23] such as DDIs and ADRs [26]. Additionally, Arab nationality was also independently associated with occurrence of pDDIs that may be attributed to older patients with multiple comorbidities and advanced disease stage in this group.

Considering the high prevalence of polypharmacy and pDDIs in the study population, we followed a linear approach and performed a negative binomial regression analysis to examine the association between the number of pDDIs and different factors associated with CKD patients. The results revealed that comorbid conditions such as dyslipidemia and diabetes increased the probability of occurrence of a pDDI by 2.7 and 1.2 folds, respectively. Furthermore, the likelihood of pDDIs increased with every one-day increase in the length of hospital stay by 1.02 times and polypharmacy increased the likelihood of pDDIs by 6.5 times. These results fortify the fact that comorbid conditions and high medication burden increase the number of potential interactions.

CKD is a well-documented risk factor for the occurrence of ADRs. Elderly CKD patients are at higher risk of developing ADRs due to multimorbidity, polypharmacy, and age, as well as CKD-related variations in drug pharmacokinetics and pharmacodynamics [9]. The incidence of ADRs in the present study was 10.7%, which is lower than the findings of a study conducted in India that reported an overall ADR incidence of 12.9% in its CKD population [27]. However, our reported ADR incidence was similar to a study conducted in the UAE in which during the hospital stay, 12.1% of CKD patients experienced a definite or probable ADR [28].

Angiotensin receptor blockers (valsartan), dipeptidyl peptidase-4 inhibitors (linagliptin), and diuretics (furosemide) were the most common drugs implicated in ADRs in our study. Previous studies conducted in CKD patients also reported involvement of these medication classes in the occurrence of ADRs [9,28]. Hyperkalemia, hypoglycemia, and hypokalemia were the most common ADRs reported in the study population. These findings may be attributed to the fact that valsartan, linagliptin, and furosemide were common medications implicated in these ADRs, which are known to cause hyperkalemia, hypoglycemia, and hypokalemia, respectively.

Regarding drug-related causality, the majority of the ADRs in the study were possible, followed by probable and definite. Similar causality pattern was reported by a study conducted in a tertiary care teaching hospital in India in which the majority of the ADRs (57.7%) were classified as possible, followed by probable (42.2%) [27]. Moreover, the ADRs observed in our study were of mild and moderate severity, which is in line with the severity assessment of ADRs reported by a study among CKD patients hospitalized in a public healthcare center [29]. Remedial action was taken for the appropriate management of the observed ADRs. These remedial actions included withdrawing the suspected drug in most cases, altering the dose in one-third of the cases, and no change for the remaining cases.

Identification and evaluation of drug-related problems, such as DDIs and ADRs, in complex CKD population is a challenging task; nevertheless, it is very important to assess the outcomes and their impact on these vulnerable patients. Early identification, timely management, and resolution of these drug-related problems can play a vital role in minimizing the associated morbidity and mortality.

There were certain limitations to our study. First, its single-centered design with a small sample size restricts the generalizability of the results. Second, the study site was a government hospital and its results may vary from hospitals in different geographical areas with other specialties. Third, the cross-sectional nature of the study limits the causal inference of the identified relationships. Fourth, pDDIs reported in this study were discovered theoretically and may not present clinically.

Conclusions

This study investigated two important drug-related problems, pDDIs and ADRs, in CKD population. High proportion of CKD patients in the study had pDDIs. The level of concern for most pDDIs was mild to moderate. Polypharmacy was an independent predictor of occurrence of pDDIs. Length of hospital stay and comorbid conditions, such as dyslipidemia and diabetes mellitus, were significantly associated with increased likelihood of pDDIs. Furthermore, there was a burden of ADRs in the study population, of which most ADRs were possible and of mild to moderate severity.

High prevalence of drug-related problems in CKD patients is a significant challenge as it influences morbidity, mortality, and quality of life of these patients. Prevention, identification, and resolution of these problems can play a vital role in achieving better clinical outcomes, which can be achieved through medication optimization. Medication optimization in CKD patients requires a proactive interdisciplinary
collaboration between clinicians, clinical pharmacists, and other healthcare professionals.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. Ministry of Health and Prevention Research Ethics Committee/RAK Subcommittee issued approval MOHAP/REC/2019/44-2019-PG-P.

**Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue.

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**Acknowledgements**

The authors would like to thank the administration of Ibrahim Bin Hamad Obaidullah Hospital, Ras Al Khaimah, UAE. The authors would also thank Dr. S Gurumadhva Rao, President, and Dr. Padma GM Rao, Dean, RAK College of Pharmacy, RAK Medical and Health Sciences University for their support and encouragement.

**References**

1. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020, 395:709-33. 10.1016/s0140-6736(20)30045-3

2. MacRae C, Mercer SW, Guenthner B, Henderson D: Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br J Gen Pract. 2021, 71:e245-9. 10.3399/bjgp20X714125

3. Schmidt IM, Hübner S, Nadal J, et al.: Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clin J Kidn Dis. 2019, 12:665-72. 10.1093/ckj/sfx046.

4. Rochon PA, Petrovic M, Cherubini A, et al.: Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Health Longev. 2021, 2:290-300. 10.1016/j.jchl.2021.09.005-4.

5. Whittaker CF, Fink JC: Deprescribing in CKD: the proof is in the process . Am J Kidney Dis. 2017, 70:596-8. 10.1053/j.ajkd.2017.05.025.

6. Shouqair TM, Rabbani SA, Kurian MT: Patterns of drug use and polypharmacy burden in chronic kidney disease patients: an experience from a secondary care hospital in United Arab Emirates. Int J Clin Pharm Ther. 2021, 59:519-29. 10.5414/CP20951.

7. Hines LE, Murphy JE: Potentially harmful drug–drug interactions in the elderly: a review . Am J Geriatr Pharmacother. 2011, 9:564-77. 10.1016/j.amjpharm.2011.10.004

8. Papotti B, Marchi C, Adorni MP, Potì F: Drug–drug interactions in polypharmacy patients: the impact of renal impairment. Curr Res Pharmacol Drug Discov. 2021, 1:100020. 10.1016/j.crphar.2021.100020

9. Laville SM, Gras-Champel V, Moragny J, et al.: Adverse drug reactions in patients with CKD. Clin J Am Soc Nephrol. 2020, 15:1090-102. 10.2215/CJN.01050120.

10. Spanakis M, Roubedaki M, Tzanakis I, Zografakis-Sfakianakis M, Patelarou E, Patelarou A: Impact of adverse drug reactions in patients with end stage renal disease in Greece. Int J Nephrol. 2019, 7568(21)00054-4.

11. Nair MR, Arora A, Ramesh K, et al.: Drug-related problems and associated factors among patients admitted with chronic kidney disease at Jipmer, Pondicherry, India. Asian J Pharm Clin Res. 2014, 7:314-7. 10.5414/crph172929101.

12. Schütze A, Hohmann C, Haubitz M, Radziwill R, Benöhr P: Medicines optimization for patients with chronic kidney disease in the outpatient setting: the role of the clinical pharmacist. Int J Pharm Pract. 2021, 29:587-97. 10.1095/ijpp19729189.

13. Richards N, Hassan M, Saleh AK, et al.: The impact of comorbidity on the quality of care for patients with chronic kidney disease in the United Arab Emirates: a population-based study. PLoS One. 2018, 13:e0199920. 10.1371/journal.pone.0199920.

14. Recalde J, Arancio S, Simeonov B, et al.: The impact of comorbidity on healthcare costs and outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Int J Environ Res Public Health. 2020, 17:9101. 10.3390/ijerph1712929101.

15. Naranjo CA, Busto U, Sellers EM, et al.: A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther. 1981, 30:239-45. 10.1038/clpt.1981.154.

16. World Health Organization: The use of the WHO-UMC system for standardisation case causality assessment . (2022). Accessed: January 30, 2022: https://www.whoint/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf.
19. Hartwig SC, Siegel J, Schneider PJ: Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992, 49:2229-32. 10.1093/ajhp/49.9.2229
20. Schumock GT, Thornton JP: Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992, 27:538.
21. Al-Ramahi R, Raddad AR, Rashed AO, Bsharat A, Abu-Ghazaleh D, Yasin E, Shehab O: Evaluation of potential drug-drug interactions among Palestinian hemodialysis patients. BMC Nephrol. 2016, 17:96. 10.1186/s12882-016-0517-4
22. Chaudhary SK, Manadhar N, Adhikari L: Polypharmacy and potential drug-drug interactions among medications prescribed to chronic kidney disease patients. Janaki Med Coll J Med Sci. 2021, 9:25-32. 10.3126/jmcjms.v9i1.38047
23. Santos-Díaz G, Pérez-Pico AM, Suárez-Santisteban MÁ, García-Bernalt V, Mayordomo R, Dorado P: Prevalence of potential drug-drug interaction risk among chronic kidney disease patients in a Spanish hospital. Pharmaceuticals. 2020, 12:10.3390/pharmaceutics12080713
24. Fasipe OJ, Olayemi SO, Akinyede AA, Osho PO, Ibiyemi-Fasipe OB, Osho ES: How do we prevent the burden of extremely harmful and clinically nonbeneficial drug-drug interactions among chronic kidney disease patients?. Toxcol Res Appl. 2018, 2:239784731879486. 10.1177/2397847318794861
25. Garín N, Sole N, Lucas B, et al.: Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021, 11:883. 10.1038/s41598-020-80560-2
26. Sommer J, Seeling A, Rupprecht H: Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy. Drugs Aging. 2020, 37:359-72. 10.1007/s40266-020-00747-0
27. Kareem SA, Sridhar SB, Shetty MF: Intensive monitoring of adverse drug reactions in nephrology unit of tertiary care teaching hospital. Saudi J Kidney Dis Transpl. 2019, 30:1057-85. 10.4103/1319-2442.270263
28. Sharif-Askari FS, Syed Sulaiman SA, Saheb Sharif-Askari N, Al Sayed Hussain A: Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease. PLoS One. 2014, 9:e95991. 10.1371/journal.pone.0095991
29. Danial M, Hassali MA, Ong LM, Khan AH: Survivability of hospitalized chronic kidney disease (CKD) patients with moderate to severe estimated glomerular filtration rate (eGFR) after experiencing adverse drug reactions (ADRs) in a public healthcare center: a retrospective 3 year study. BMC Pharmacol Toxicol. 2018, 19:52. 10.1186/s40360-018-0245-0